BridgeMD
Tests treatment safety and results for Advanced Solid Tumors
Official title A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
ClinicalTrials.gov ID: NCT07060989
What this study is testing
What is NTS071?
NTS071 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for advanced solid tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female people, ≥ 18 years
- Advanced solid tumors with TP53 Y220C mutation
- Previously treated with one or more lines of anticancer therapy and progressive disease
- At least one measurable lesion according to RECIST version 1.1 criteria
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
You likely can't join if
- Known CNS primary tumor and active or untreated CNS metastases
- History of another primary malignancy that has been diagnosed or required therapy within the past 2 years
- Toxicities of prior therapy have not been resolved to ≤ Grade 1 or to baseline
- Significant cardiovascular disease, including congestive heart failure
- Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active
- Have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the...
See the full eligibility criteria
- Male or female people, ≥ 18 years
- Advanced solid tumors with TP53 Y220C mutation
- Previously treated with one or more lines of anticancer therapy and progressive disease
- At least one measurable lesion according to RECIST version 1.1 criteria
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Adequate organ and bone marrow function
- Known CNS primary tumor and active or untreated CNS metastases
- History of another primary malignancy that has been diagnosed or required therapy within the past 2 years
- Toxicities of prior therapy have not been resolved to ≤ Grade 1 or to baseline
- Significant cardiovascular disease, including congestive heart failure
- Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active
- Have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
The study team makes the final eligibility decision.
Where it's taking place
- San Antonio, Texas, United States
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include San Antonio, Texas, United States; Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.